Loading…
Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia
Ceftazidime and cefamandole were compared in a randomized multicentre trial in hospitalized patients with pneumonia. Of 290 patients enrolled, 92 patients in the ceftazidime group and 71 patients in the cefamandole group were evaluable. Geometric mean MICs of organisms isolated and tested to ceftazi...
Saved in:
| Published in: | Journal of antimicrobial chemotherapy 1986-10, Vol.18 (4), p.521-529 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | 529 |
| container_issue | 4 |
| container_start_page | 521 |
| container_title | Journal of antimicrobial chemotherapy |
| container_volume | 18 |
| creator | YANGCO, B. G PALUMBO, J. A NOLEN, T LIFLAND, P. W SCHLEUPNER, C. J |
| description | Ceftazidime and cefamandole were compared in a randomized multicentre trial in hospitalized patients with pneumonia. Of 290 patients enrolled, 92 patients in the ceftazidime group and 71 patients in the cefamandole group were evaluable. Geometric mean MICs of organisms isolated and tested to ceftazidime were within achievable therapeutic serum concentrations of ceftazidime. Satisfactory clinical responses were observed in 91% (84/92) of ceftazidime-treated patients and 83% (59/71) of cefamandole-treated patients (P greater than 0.05). Superinfection occurred in one (1%) ceftazidime-treated patient and in five (7%) cefamandole-treated patients. Side effects were infrequent with either treatment. Ceftazidime is as safe and effective as cefamandole for the treatment of pneumonia due to a variety of Gram-positive and Gram-negative pathogens. |
| format | article |
| fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_3533891</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3533891</sourcerecordid><originalsourceid>FETCH-LOGICAL-p821-be56505153693517a8bf28d18b7821224be9a448f52caa2a540001bd4fa352533</originalsourceid><addsrcrecordid>eNo9j8tqwzAUREVpSdO0n1DQoluDXteWlyX0BYFusg_X8hVVsWwj2YH06-vQ0NXAnGHgXLG1NKUolKjlNVsLLaCoDOhbdpfztxCihNKu2EqD1raWaxa3Qxwx4RSOxOPcTcFRPyXidMRuXuqh54Pn0xfxjJ6mE8e-5eR9cOhOZ-TIT_gT2hCJHynlOZ8rjMtu6Ij7IfGxpzkOfcB7duOxy_RwyQ3bv77st-_F7vPtY_u8K0arZNEQlCBAgi5rDbJC23hlW2mbasFKmYZqNMZ6UA5RIZhFTDat8ahBLWYb9vh3O85NpPYwphAxnQ4X64U_XThmh51P2LuQ_2eVrU0JUv8C2d1iYQ</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia</title><source>Oxford University Press:Jisc Collections:Oxford Journal Archive: Access period 2024-2025</source><creator>YANGCO, B. G ; PALUMBO, J. A ; NOLEN, T ; LIFLAND, P. W ; SCHLEUPNER, C. J</creator><creatorcontrib>YANGCO, B. G ; PALUMBO, J. A ; NOLEN, T ; LIFLAND, P. W ; SCHLEUPNER, C. J</creatorcontrib><description>Ceftazidime and cefamandole were compared in a randomized multicentre trial in hospitalized patients with pneumonia. Of 290 patients enrolled, 92 patients in the ceftazidime group and 71 patients in the cefamandole group were evaluable. Geometric mean MICs of organisms isolated and tested to ceftazidime were within achievable therapeutic serum concentrations of ceftazidime. Satisfactory clinical responses were observed in 91% (84/92) of ceftazidime-treated patients and 83% (59/71) of cefamandole-treated patients (P greater than 0.05). Superinfection occurred in one (1%) ceftazidime-treated patient and in five (7%) cefamandole-treated patients. Side effects were infrequent with either treatment. Ceftazidime is as safe and effective as cefamandole for the treatment of pneumonia due to a variety of Gram-positive and Gram-negative pathogens.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>PMID: 3533891</identifier><identifier>CODEN: JACHDX</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; Aged ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Bacteria - drug effects ; Biological and medical sciences ; Cefamandole - adverse effects ; Cefamandole - pharmacology ; Cefamandole - therapeutic use ; Ceftazidime - adverse effects ; Ceftazidime - pharmacology ; Ceftazidime - therapeutic use ; Humans ; Medical sciences ; Microbial Sensitivity Tests ; Middle Aged ; Pharmacology. Drug treatments ; Pneumonia - drug therapy ; Pneumonia - etiology ; Pneumonia - microbiology</subject><ispartof>Journal of antimicrobial chemotherapy, 1986-10, Vol.18 (4), p.521-529</ispartof><rights>1987 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7894651$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3533891$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>YANGCO, B. G</creatorcontrib><creatorcontrib>PALUMBO, J. A</creatorcontrib><creatorcontrib>NOLEN, T</creatorcontrib><creatorcontrib>LIFLAND, P. W</creatorcontrib><creatorcontrib>SCHLEUPNER, C. J</creatorcontrib><title>Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>Ceftazidime and cefamandole were compared in a randomized multicentre trial in hospitalized patients with pneumonia. Of 290 patients enrolled, 92 patients in the ceftazidime group and 71 patients in the cefamandole group were evaluable. Geometric mean MICs of organisms isolated and tested to ceftazidime were within achievable therapeutic serum concentrations of ceftazidime. Satisfactory clinical responses were observed in 91% (84/92) of ceftazidime-treated patients and 83% (59/71) of cefamandole-treated patients (P greater than 0.05). Superinfection occurred in one (1%) ceftazidime-treated patient and in five (7%) cefamandole-treated patients. Side effects were infrequent with either treatment. Ceftazidime is as safe and effective as cefamandole for the treatment of pneumonia due to a variety of Gram-positive and Gram-negative pathogens.</description><subject>Adult</subject><subject>Aged</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Bacteria - drug effects</subject><subject>Biological and medical sciences</subject><subject>Cefamandole - adverse effects</subject><subject>Cefamandole - pharmacology</subject><subject>Cefamandole - therapeutic use</subject><subject>Ceftazidime - adverse effects</subject><subject>Ceftazidime - pharmacology</subject><subject>Ceftazidime - therapeutic use</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Pneumonia - drug therapy</subject><subject>Pneumonia - etiology</subject><subject>Pneumonia - microbiology</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1986</creationdate><recordtype>article</recordtype><recordid>eNo9j8tqwzAUREVpSdO0n1DQoluDXteWlyX0BYFusg_X8hVVsWwj2YH06-vQ0NXAnGHgXLG1NKUolKjlNVsLLaCoDOhbdpfztxCihNKu2EqD1raWaxa3Qxwx4RSOxOPcTcFRPyXidMRuXuqh54Pn0xfxjJ6mE8e-5eR9cOhOZ-TIT_gT2hCJHynlOZ8rjMtu6Ij7IfGxpzkOfcB7duOxy_RwyQ3bv77st-_F7vPtY_u8K0arZNEQlCBAgi5rDbJC23hlW2mbasFKmYZqNMZ6UA5RIZhFTDat8ahBLWYb9vh3O85NpPYwphAxnQ4X64U_XThmh51P2LuQ_2eVrU0JUv8C2d1iYQ</recordid><startdate>198610</startdate><enddate>198610</enddate><creator>YANGCO, B. G</creator><creator>PALUMBO, J. A</creator><creator>NOLEN, T</creator><creator>LIFLAND, P. W</creator><creator>SCHLEUPNER, C. J</creator><general>Oxford University Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>198610</creationdate><title>Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia</title><author>YANGCO, B. G ; PALUMBO, J. A ; NOLEN, T ; LIFLAND, P. W ; SCHLEUPNER, C. J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p821-be56505153693517a8bf28d18b7821224be9a448f52caa2a540001bd4fa352533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1986</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Bacteria - drug effects</topic><topic>Biological and medical sciences</topic><topic>Cefamandole - adverse effects</topic><topic>Cefamandole - pharmacology</topic><topic>Cefamandole - therapeutic use</topic><topic>Ceftazidime - adverse effects</topic><topic>Ceftazidime - pharmacology</topic><topic>Ceftazidime - therapeutic use</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Pneumonia - drug therapy</topic><topic>Pneumonia - etiology</topic><topic>Pneumonia - microbiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>YANGCO, B. G</creatorcontrib><creatorcontrib>PALUMBO, J. A</creatorcontrib><creatorcontrib>NOLEN, T</creatorcontrib><creatorcontrib>LIFLAND, P. W</creatorcontrib><creatorcontrib>SCHLEUPNER, C. J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>YANGCO, B. G</au><au>PALUMBO, J. A</au><au>NOLEN, T</au><au>LIFLAND, P. W</au><au>SCHLEUPNER, C. J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>1986-10</date><risdate>1986</risdate><volume>18</volume><issue>4</issue><spage>521</spage><epage>529</epage><pages>521-529</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><coden>JACHDX</coden><abstract>Ceftazidime and cefamandole were compared in a randomized multicentre trial in hospitalized patients with pneumonia. Of 290 patients enrolled, 92 patients in the ceftazidime group and 71 patients in the cefamandole group were evaluable. Geometric mean MICs of organisms isolated and tested to ceftazidime were within achievable therapeutic serum concentrations of ceftazidime. Satisfactory clinical responses were observed in 91% (84/92) of ceftazidime-treated patients and 83% (59/71) of cefamandole-treated patients (P greater than 0.05). Superinfection occurred in one (1%) ceftazidime-treated patient and in five (7%) cefamandole-treated patients. Side effects were infrequent with either treatment. Ceftazidime is as safe and effective as cefamandole for the treatment of pneumonia due to a variety of Gram-positive and Gram-negative pathogens.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>3533891</pmid><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0305-7453 |
| ispartof | Journal of antimicrobial chemotherapy, 1986-10, Vol.18 (4), p.521-529 |
| issn | 0305-7453 1460-2091 |
| language | eng |
| recordid | cdi_pubmed_primary_3533891 |
| source | Oxford University Press:Jisc Collections:Oxford Journal Archive: Access period 2024-2025 |
| subjects | Adult Aged Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Bacteria - drug effects Biological and medical sciences Cefamandole - adverse effects Cefamandole - pharmacology Cefamandole - therapeutic use Ceftazidime - adverse effects Ceftazidime - pharmacology Ceftazidime - therapeutic use Humans Medical sciences Microbial Sensitivity Tests Middle Aged Pharmacology. Drug treatments Pneumonia - drug therapy Pneumonia - etiology Pneumonia - microbiology |
| title | Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T05%3A00%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20multicentre%20evaluation%20of%20the%20safety%20and%20efficacy%20of%20ceftazidime%20versus%20cefamandole%20for%20pneumonia&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=YANGCO,%20B.%20G&rft.date=1986-10&rft.volume=18&rft.issue=4&rft.spage=521&rft.epage=529&rft.pages=521-529&rft.issn=0305-7453&rft.eissn=1460-2091&rft.coden=JACHDX&rft_id=info:doi/&rft_dat=%3Cpubmed_pasca%3E3533891%3C/pubmed_pasca%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p821-be56505153693517a8bf28d18b7821224be9a448f52caa2a540001bd4fa352533%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/3533891&rfr_iscdi=true |